α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study

International Journal of Urology

Volumn 20, Issue 4, 2013, Pages 421-428

  Masumori, Naoya ^a   Tsukamoto, Taiji ^a   Horita, Hiroki ^c   Sunaoshi, Ken ichi ^b   Tanaka, Yoshinori ^d   Takeyama, Koh ^e   Sato, Eiji ^f   Miyao, Noriomi ^g  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hokkaido Social Insurance Hospital   (Japan)

^c Saiseikai Otaru Hospital   (Japan)

^d Division of Urology Hokkaido Prefectural Esahi Hospital   (Japan)

^e Yakumo General Hospital   (Japan)

^f Division of Urology Akabira City General Hospital   (Japan)

^g Muroran City General Hospital   (Japan)

Author keywords

Alpha 1 blocker; Benign prostatic hyperplasia; Long term outcome; Postvoid residual urine volume; Prostate volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

AGED; ARTICLE; BLADDER NECK STENOSIS; DISEASE COURSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; HYDRONEPHROSIS; INTENTION TO TREAT ANALYSIS; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PROSTATE VOLUME; QUALITY OF LIFE INDEX; URINARY TRACT INFECTION; URINE RETENTION;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT DROPOUTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; SULFONAMIDES; TREATMENT OUTCOME; URINARY RETENTION; URINATION DISORDERS;

EID: 84875789631     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03165.x     Document Type: Article

References (24)

1. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406-413.
2. Lepor H, Kaplan SA, Klimberg I etal. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J. Urol. 1997; 157: 525-530.
3. Schulman CC, Lock TMTW, Buzelin J-M etal. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J. Urol. 2001; 168: 1358-1363.
4. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J. Urol. 2003; 170: 498-502.
5. Ichioka K, Ohara H, Terada N etal. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia. Int. J. Urol. 2004; 11: 870-875.
6. Yamanishi T, Tatssumiya K, Furuya N etal. Long-term efficacy of tamsulosin in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in real-life practice. UroToday Int. J. 2012; doi: 10.3834/uij.1944-5784.2009.02.01.
7. Kojima Y, Sasaki S, Imura M, Kubota Y, Hayashi Y, Kohri K. Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: a prospective open-label long-term study using frequency-volume chart. Neurourol. Urodynam. 2012; 31: 80-85.
8. Masumori N, Hashimoto J, Itoh N, Sapporo Medical University Naftopidil Study Group. Short-term efficacy and long-term compliance/treatment failure of the alpha 1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Scand. J. Urol. Nephrol. 2007; 41: 422-429.
9. Roehrborn CG, Siami P, Barkin J etal. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 2010; 57: 123-131.
10. Roehrborn CG, Siami P, Barkin J etal. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur. Urol. 2009; 55: 461-471.
11. Roehrborn CG, Barkin J, Siami P etal. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int. 2011; 107: 946-954.
12. Masumori N. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia. Ther. Clin. Risk Manag. 2011; 7: 227-238.
13. De la Rosette JJMCH, Kortmann BBM, Rossi C, Sonke GS, Floratos DL, Kiemeney LALM. Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms. J. Urol. 2002; 167: 1734-1739.
14. Kawachi Y, Sakurai T, Sugimura S etal. Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochloride. Scand. J. Urol. Nephrol. 2010; 44: 38-45.
15. Yokoyama T, Watanabe T, Saika T etal. Natural course of lower urinary tract symptoms following discontinuation of alpha-1-adrenergic blockers in patients with benign prostatic hyperplasia. Int. J. Urol. 2007; 14: 598-601.
16. Kaplan SA, Reis RB, Cologna A etal. Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms. Urology 1998; 52: 12-16.
17. Yanardag H, Goktas S, Kibar Y, Kilic S, Erduran D. Intermittent tamsulosin therapy in men with lower urinary tract symptoms. J. Urol. 2005; 173: 155-157.
18. Barkin J, Guimarães M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur. Urol. 2003; 44: 461-466.
19. Siami PF, Beasley K. Dutasteride with as-needed tamsulosin in men at risk of benign prostatic hypertrophy progression. UroToday Int. J. 2012; doi: http://dx.doi.org/10.3834/uij.1944-5784.2012.02.11.
20. McConnell JD, Roehrborn CG, Bautista OM etal. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2003; 349: 2387-2398.
21. Kawabe K, Homma Y, Kubota K, Sozu T, Tamsulosin Long-term Study Group. How frequent are invasive therapies required in patients receiving tamsulosin for benign prostatic hyperplasia? A retrospective long-term study. Int. J. Urol. 2006; 13: 127-131.
22. Mochtar CA, Kiemeney LALM, Laguna MP etal. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology 2005; 65: 300-305.
23. Dunsmuir WD, Feneley M, Corry DA, Bryan J, Kirby RS. The day-to-day variation (test-retest reliability) of residual urine measurement. Br. J. Urol. 1996; 77: 192-193.
24. Mochtar CA, Kiemeney LA, van Riemsdijk MM, Laguna MP, Debruyne FM, de la Rosette JJ. Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia. J. Urol. 2006; 175: 213-216.